Drug Discovery

Overview

Invicro has a vast range of tools that help accelerate your drug discovery and development process. Our technology platforms support key decision-making in:

Early discovery and screening
Candidate selection
First-in-human translation and early development
Late stage, multi-center determination of efficacy

We have experience working with a wide range of therapeutics, including small molecules, peptides, proteins, antibodies, multi-specific proteins, CAR-T cells, viruses, antisense oligonucleotides (ASO), DNA, RNA and others. Invicro strives to answer a wide array of biological questions, including but not limited to:

Target identification
Target density (Bmax)
Binding affinity (KD)
Target engagement
Target occupancy, impact of dosing regimens, and route of administration
Biodistribution and pharmacokinetics (ADME, DMPK)
Pharmacodynamics (PD)
Efficacy

Capabilities

Invicro offers in vitro assays and in vivo imaging across resolutions and sensitivities. We design studies that combine different technologies spanning various platforms, including:

in vivo

Preclinical

IVIS Bioluminescence
IVIS Fluorescence

Translational

MRI
PET
SPECT
CT
Ultrasound

Rodent Models

AAALAC accredited facilities
All Major Disease Areas
All Major Tumor Models

Larger Species

All Major Research Species
Clinical Imaging
Veterinary Radiology

ex vivo

Imaging and Radioisotopes

Cryo-fluorescence tomography (CFT)
ex vivo fluorescence imaging
Confocal microscopy
Autoradiography & micro-autoradiography
Homogenate radioligand binding assays
Gamma counting and liquid scintillation

Bioanalytical

Flow cytometry
Clinical chemistry
CBC Analysis
Urinalysis

in vitro and Chemistry

In Vitro Assays

Cell Culture
Cell binding and competition
Internalization
Tissue homogenate binding

Imaging Agent Chemistry

Imaging agent radiolabeling
- Oligos to Antibodies
- Nanoparticles
- Viruses
- Cells
Fluorescent labeling

Applications

Invicro leverages advanced tools to provide solutions to various questions in preclinical animal models (rodent to NHP) and in translational work in humans, including:

Biodistribution

What is the in vivo distribution of a compound following intrathecal administration?
Does a compound cross the BBB?
What is the rate of clearance and route of elimination of a novel antisense oligonucleotide (ASO)?
What is the fate of the cargo with respect to the carrier (e.g., for an antibody drug conjugate or a drug loaded liposome)?
What is the integrity of a novel implant material over time?
Does a novel alpha radiopharmaceutical exhibit tumor cell internalization in vivo?
What is the fate and persistence of my therapeutic T cells?
Where and for how long is my gene of interest delivered and expressed?

PD biomarkers and efficacy

Does my anti-cancer therapeutic inhibit tumor growth in an orthotopic, transgenic, or metastatic tumor model?
Can tumor accumulation of a novel radiolabeled compound predict treatment response?
Are there synergistic effects when combining an alpha radiopharmaceutical with an immunotherapy agent?
Does colon wall thickness in an animal model of IBD change following treatment?
Does my anticancer therapeutic decrease tumor burden in my deep tissue tumor model?
Does liver fat fraction or fibrosis stabilize or decrease with my treatment?
Does my immune-modulator increase T cell activation in a tumor, and with what timing?

Target Validation/Engagement

What is the receptor occupancy of a compound following oral dosing?
Does my targeted biologic bind preferentially in a target expressing tumor vs. a target negative tumor?
Does my novel drug delivery system (e.g. virus) reach its target in vivo?